CTOs on the Move


 
AllMed Healthcare Management is a utilization management and independent review organization providing comprehensive nurse and physician review solutions to payer and provider organizations nationwide. Our clients include leading health plans, medical management organizations, TPAs, disability carriers, hospital groups and ambulatory surgery centers. Services are deployed through PeerPoint, AllMed`s state-of-the-art medical review portal.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.allmedmd.com
  • 111 SouthWest Fifth Avenue Suite 1400
    Portland, OR USA 97204
  • Phone: 800.400.9916

Executives

Name Title Contact Details
Jeff Keating
Chief Technology Officer Profile

Similar Companies

canfield scientific inc

canfield scientific inc is a Fairfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hyperion Technology Group

Hyperion Technology Group is a defense and space company based in Madrid, Spain.

Vermont Nurse Alliance of Vermont and New Hampshire

Visiting Nurse and Hospice for Vermont and New Hampshire (VNH) is a non‐profit organization that has provided home health and hospice care services in Vermont and New Hampshire since 1907. The agency is dedicated to delivering outstanding home- and community-based health and hospice services that enrich the lives of the people they serve. VNH makes home visits to people of all ages and all stages of life – regardless of ability to pay – and also provides communities with education and wellness programs. Currently, VNH serves more than 150 towns in Vermont and New Hampshire and covers 4,000 square miles. VNH caregivers provide services for more than 5,000 people each year and makes more than 150,000 home visits to people of all ages and at all stages of life.

Cryopen

Cryopen is a Covington, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.